Its a big pharma showdown as health care analyst David Williamson discusses whether Merck (NYSE: MRK) or Pfizer (NYSE: PFE) is the better buy. Both stocks have a lot going for them, Merck an exciting pipeline featuring a likely first to market immuno-oncology drug, a hepatitus-c cure, and even a potential treatment for Alzheimer's. Pfizer has a sizable cash horde and an aggressive management team. While losing out on the lower taxes an AstraZeneca deal would have brought, shareholders can look forward to buybacks dividends and a possible huge expansion of its pneumonia vaccine.

Watch and find out in this episode of Market Check-Up, the Motley Fool's health care focused investing show which of these two stocks is the winner.


David Williamson owns shares of Merck and Pfizer. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.